Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort studyEe Vien Low, Kalaiarasu M. Peariasamy, Wei Jia Lee et al.|International Journal of Infectious Diseases|2023Cited by 15
Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence PerspectiveEe Vien Low, Kalaiarasu M. Peariasamy, Hoon Shien Teh et al.|Drugs - Real World Outcomes|2024Cited by 9